GlassScriptPhysician profile
Sunil H Patel
NPI 1730150848
$17,744.49
in general payments reported to CMS, 2019-2025
69 companies · $2,249 in 2025
The $2,249 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,013 · 2020: $2,485 · 2021: $3,545 · 2022: $2,202 · 2023: $2,375 · 2024: $1,874 · 2025: $2,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,448 · Education: $50.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,447.94 |
| Education | $50.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,932.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $2,594.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $1,151.50 | 2019-2025 | Verquvo, Zerbaxa, Dificid |
| Lilly USA, LLC | $1,109.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $764.12 | 2019-2023 | |
| Amgen INC. | $700.60 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $658.58 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $650.18 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $645.89 | 2019-2023 | Livalo, Seglentis |
| Esperion Therapeutics, INC. | $588.98 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $539.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.06 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $483.16 | 2019-2024 | Xarelto |
| Sumitomo Pharma America, INC. | $393.16 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $329.79 | 2019-2025 |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $327.82 | 2021-2025 | |
| Amarin Pharma, INC. | $262.17 | 2019-2022 | |
| Astellas Pharma US INC | $241.13 | 2020-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $192.30 | 2023-2025 | Rexulti, Nuedexta, Jynarque |
| Abbott Laboratories | $184.45 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.33 | 2019-2025 | Relistor, Xifaxan |
| Ucb, INC. | $183.14 | 2019-2024 | Briviact |
| Vanda Pharmaceuticals INC. | $173.14 | 2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $134.25 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $125.67 | 2021-2024 | Gvoke Hypopen |
| Alnylam Pharmaceuticals INC. | $125.00 | 2023 | Amvuttra |
| Allergan, INC. | $92.74 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $89.24 | 2019-2022 | |
| Eisai INC. | $82.99 | 2022-2025 | |
| Acadia Pharmaceuticals INC | $74.48 | 2019-2022 | |
| Corcept Therapeutics | $74.27 | 2019-2025 | Korlym |
| Lundbeck LLC | $73.09 | 2022-2025 | Rexulti |
| Akebia Therapeutics INC | $72.42 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $68.03 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $64.69 | 2019-2023 | Eliquis |
| Radius Health, INC. | $56.69 | 2020-2021 | |
| Mylan Specialty L.P. | $49.77 | 2019-2021 | |
| Exact Sciences Corporation | $42.29 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $42.01 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $37.32 | 2021 | |
| Lifescan, INC. | $36.33 | 2020-2021 | |
| Genentech USA, INC. | $36.11 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.93 | 2022 | |
| Insmed, INC. | $31.97 | 2025 | Arikayce |
| Neurocrine Biosciences, INC. | $31.48 | 2022 | |
| Horizon Therapeutics Plc | $29.08 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $28.63 | 2021 | |
| Vifor Pharma, INC. | $27.67 | 2021 | |
| Axsome Therapeutics, INC. | $26.67 | 2024 | Auvelity |
| Nestle Healthcare Nutrition INC. | $23.60 | 2021 | |
| Cequr Corporation | $21.82 | 2023 | Cequr Simplicity |
| Arbor Pharmaceuticals, INC. | $20.38 | 2021 | |
| Dexcom, INC. | $20.21 | 2024 | Dexcom G6 Transmitter |
| Analog Devices INC. | $20.19 | 2024 | Sensinel Cpm Wearable |
| Alfasigma USA, INC. | $20.04 | 2022 | |
| Boston Scientific Corporation | $19.52 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.10 | 2022 | |
| Qiagen, LLC | $18.72 | 2020 | |
| Philips North America LLC | $18.50 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Takeda Pharmaceuticals U.S.A., INC. | $18.44 | 2021 | |
| Supernus Pharmaceuticals, INC. | $17.94 | 2021 | |
| Nevro Corp. | $17.08 | 2024 | Senza |
| Argenx US, INC. | $17.02 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Mannkind Corporation | $16.87 | 2019 | |
| Bigfoot Biomedical INC | $16.04 | 2022 | |
| Biogen, INC. | $15.36 | 2019 | |
| Paratek Pharmaceuticals, INC. | $13.77 | 2025 | Nuzyra |
| Redhill Biopharma INC. | $12.96 | 2021 | |
| Hikma Pharmaceuticals USA | $11.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.